RedHill Biopharma (RDHL) Corporate presentation summary

Corporate and financial overview

• Focuses on U.S. commercialization and development of proprietary drugs for GI, infectious diseases, and oncology, with a strong U.S. commercial footprint and robust late-stage pipeline.

• FY 2025 net revenues were $7.8M, with a cash balance of $4.1M and gross margin of 74.6%.

• Equity financing capacity stands at $31.7M, with a market cap of approximately $5M as of July 2026.

• Strategic partnership with Cumberland Pharmaceuticals for Talicia, including a $4M investment and co-commercialization.

Key commercial product: Talicia®

• Talicia® (omeprazole magnesium, amoxicillin, rifabutin) is FDA-approved for H. pylori infection in adults and launched in the U.S. and UAE.

• Listed as a first-line H. pylori treatment by the American College of Gastroenterology and covered by major U.S. formularies.

• Demonstrated >90% eradication rates in adherent populations and negligible resistance to component antibiotics.

• U.S. patent protection until 2042 and FDA QIDP designation, providing market exclusivity through 2027.

• Broad managed care coverage, including government and commercial plans, with preferred status on major formularies.

Clinical and R&D pipeline highlights

• RHB-102 (Bekinda®): Extended-release ondansetron for GI intolerance, gastroenteritis, IBS-D, and oncology support; positive Phase 3 and Phase 2 results.

• RHB-204: Fixed-dose antibiotic combination for Crohn's disease (MAP+ patients) and pulmonary NTM disease; Phase 2 study planned, supported by positive RHB-104 Phase 3 data.

• Opaganib: First-in-class SPHK2 inhibitor for oncology, COVID-19, Ebola, metabolic, and inflammatory diseases; ongoing Phase 2 studies and positive COVID-19 Phase 2/3 data.

• RHB-107 (upamostat): Host-directed serine protease inhibitor for COVID-19 and oncology; positive Phase 2 COVID-19 data.